Core Viewpoint - WuXi AppTec has raised its full-year revenue forecast for the second time this year, now expecting revenue to reach between 43.5 billion to 44 billion yuan, up from the previous estimate of 42.5 billion to 43.5 billion yuan, reflecting strong business performance and confidence in future profitability [1] Financial Performance - For the first three quarters of this year, WuXi AppTec reported total revenue of 32.86 billion yuan, representing an 18.6% year-on-year increase [1] - The net profit attributable to shareholders reached 12.076 billion yuan, a significant increase of 84.84% year-on-year [1] - Adjusted non-IFRS net profit was 10.54 billion yuan, up 43.4% year-on-year, with the adjusted non-IFRS net profit margin increasing by 5.6 percentage points to 32.1% [1] Business Segments - The chemical business, which is the largest revenue source for WuXi AppTec, generated 25.98 billion yuan in revenue for the first three quarters, marking a 29.3% year-on-year growth [2] - The TIDES business (oligonucleotides and peptides) within the chemical segment saw revenue reach 7.84 billion yuan, a remarkable 121.1% increase year-on-year, with a 17.1% growth in orders on hand as of September 30 [2] Order Backlog and Market Trends - As of the end of September, WuXi AppTec's order backlog stood at 59.88 billion yuan, reflecting a 41.2% year-on-year increase [3] - The biotechnology sector in A-shares and Hong Kong has seen a resurgence in refinancing, which may lead to increased R&D investments and more outsourcing orders for contract research organizations [3] Clinical Early-stage Business - The early-stage clinical business remains under pressure, with testing services generating 4.169 billion yuan in revenue, a slight decline of 0.04% year-on-year, primarily due to market pricing factors [3] - The biological services segment achieved revenue of 1.947 billion yuan, showing only a modest growth of 6.64% year-on-year [3] Strategic Divestiture - WuXi AppTec announced plans to sell its China clinical research services business to Hillhouse Capital for a total price of 2.8 billion yuan, which will be classified as discontinued operations in the 2025 annual report [3][4] - This divestiture aligns with the company's strategy to focus on the CRDMO business model and enhance its global capabilities and capacity [4]

Core Viewpoint - WuXi AppTec (02359) announced a sale agreement where its wholly-owned subsidiary, Shanghai WuXi AppTec New Drug Development Co., Ltd., will sell its shares in Shanghai Kande Hongyi Medical Clinical Research Co., Ltd. and Shanghai WuXi Jinshi Pharmaceutical Technology Co., Ltd. to Hillhouse Capital for cash consideration, reflecting the company's strategic focus on its core CRDMO business model [1] Group 1 - The transaction is expected to provide financial support to accelerate global capabilities and capacity development, enhancing service to clients and benefiting global patients [1] - Hillhouse Capital is recognized as a leading global private asset management firm, focusing on sectors such as healthcare, manufacturing, green energy, hard technology, and consumer technology [1] Group 2 - From January to September 2025, Kande Hongyi and Jinshi Pharmaceutical generated a total revenue of RMB 1.16 billion (unaudited), accounting for approximately 3.5% of the company's unaudited revenue for the first three quarters of 2025 [1] - During the same period, the net profit from Kande Hongyi and Jinshi Pharmaceutical amounted to RMB 90 million (unaudited), representing about 0.7% of the company's unaudited net profit for the first three quarters of 2025 [1]

Core Viewpoint - WuXi AppTec reported strong financial performance for Q3 2023, with significant year-on-year growth in revenue and net profit, while also announcing a strategic asset sale to Hillhouse Capital for 2.8 billion RMB [1][3][4]. Financial Performance - For the first three quarters of 2023, WuXi AppTec achieved revenue of 32.86 billion RMB, an increase of 18.61% year-on-year, and a net profit attributable to shareholders of 12.08 billion RMB, up 84.84% [2]. - In Q3 2023 alone, the company reported revenue of 12.06 billion RMB, reflecting a 15.26% year-on-year growth, and a net profit of 3.51 billion RMB, which is a 53.27% increase [2]. - The basic earnings per share for Q3 was 1.24 RMB, up 55.00%, while diluted earnings per share was 1.22 RMB, an increase of 54.43% [2]. Business Outlook - WuXi AppTec expects its revenue from continuing operations to return to double-digit growth, with the growth rate revised from 13%-17% to 17%-18% for 2025 [3]. - The overall revenue forecast for the year has been adjusted from 42.5-43.5 billion RMB to 43.5-44 billion RMB [3]. Strategic Asset Sale - The company plans to sell 100% equity of its subsidiaries, Shanghai Kande Hongyi Medical Research Co., Ltd. and Shanghai WuXi Jinshi Pharmaceutical Technology Co., Ltd., to Hillhouse Capital for 2.8 billion RMB [3][4]. - This divestment aligns with the company's strategy to focus on its CRDMO core business and enhance operational efficiency [4]. Market Performance - WuXi AppTec's stock has seen a significant increase, with a year-to-date rise of over 140%, closing at 103.81 RMB per share, resulting in a market capitalization exceeding 300 billion RMB [5].

Core Insights - WuXi AppTec (603259.SH/2359.HK) reported its Q3 financial results on October 26, 2025, highlighting significant growth in its TIDES business and advancements in production capacity [1] Financial Performance - The company achieved TIDES business revenue of 7.84 billion yuan in the first three quarters, representing a year-on-year increase of 121.1% [1] Production Capacity - WuXi AppTec has completed the construction of its Taiqing peptide production capacity ahead of schedule, with over 10 WL of solid-phase synthesis reaction vessels operational in Q3, one quarter earlier than previously anticipated [1]

Core Insights - WuXi AppTec (02359) reported a revenue of RMB 32.86 billion for the first three quarters of 2025, representing a year-on-year growth of 18.6% [1] - The revenue from continuing operations increased by 22.5% year-on-year [1] - The net profit attributable to shareholders reached RMB 12.076 billion, showing a significant year-on-year increase of 84.84% [1] - Basic earnings per share stood at RMB 4.25 [1] Revenue Projections - The company expects revenue from continuing operations to return to double-digit growth, with the growth rate revised from 13-17% to 17-18% [1] - The overall revenue forecast for the year has been adjusted from RMB 42.5-43.5 billion to RMB 43.5-44 billion [1] Business Focus - The company will concentrate on its CRDMO core business and aims to continuously improve operational efficiency [1]

格隆汇10月26日丨药明康德(02359.HK)公告，公司2025年前三季度实现营业收入328.57亿元，同比增长 18.61%；归属于上市公司股东的净利润120.76亿元，同比增幅84.84%。基本每股收益4.25元。 公司持续聚焦及加强CRDMO业务模式，营业收入持续增长，同时持续优化生产工艺和经营效率，以及 临床后期和商业化大项目增长带来的产能效率不断提升，提高了整体的盈利能力；同时，公司出售持有 的联营企业WuXi XDC CaymanInc.部分股票的收益，进一步提升了公司的利润。 ...

WUXI APPTEC CO., LTD. * 無錫藥明康德新藥開發股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2359） 海外監管公告 本海外監管公告乃由本公司根據香港聯合交易所有限公司證券上市規則第 13.10B條作出。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因依賴該等內容而引致之任何損失承擔任何責任。 茲載列本公司在上海證券交易所網站刊登的以下資料中文全文，僅供參閱。 承董事會命 無錫藥明康德新藥開發股份有限公司 董事長 李革博士 香港，2025年10月26日 截至本公告日期，本公司董事會包括執行董事李革博士、陳民章博士、楊青博士及張朝暉先生； 非執行董事童小幪先生及吳亦兵博士；以及獨立非執行董事盧韶華女士、俞衛博士、張新博士、 詹智玲女士及冷雪松先生。 * 僅供識別 证券代码：603259 证券简称：药明康德 公告编号：临 2025-069 无锡药明康德新药开发股份有限公司 2、上述交易简要内容所述的交易对价作为基准股权转让价款，尚需根据目 标公司于放 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因依賴該等內容而引致之任何損失承擔任何責任。 海外監管公告 本海外監管公告乃由本公司根據香港聯合交易所有限公司證券上市規則第 13.10B條作出。 茲載列本公司在上海證券交易所網站刊登的以下資料中文全文，僅供參閱。 承董事會命 無錫藥明康德新藥開發股份有限公司 董事長 WUXI APPTEC CO., LTD. * 無錫藥明康德新藥開發股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2359） 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 无锡药明康德新药开发股份有限公司（以下简称"本公司"或"公司"）于 2025 年 10 月 10 日及 2025 年 10 月 23 日向本公司全体董事发出会议通知及会议 材料，全体董事一致同意豁免本次会议的通知期限要求，并以现场结合通讯表决 方式于 2025 年 10 月 24 日 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部份內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 WUXI APPTEC CO., LTD. * 無錫藥明康德新藥開發股份有限公司 有關出售附屬公司的 業務發展最新情況 於2025年10月24日，本公司全資子公司上海藥明康德新藥開發有限公司（「上海 藥明」）與高瓴投資（「高瓴」）訂立買賣協議（「買賣協議」），據此，上海藥明同意 按現金對價出售，而高瓴同意購買其所持有的上海康德弘翼醫學臨床研究有 限公司（「康德弘翼」）及上海藥明津石醫藥科技有限公司（「津石醫藥」）所有股 份（「本次交易」）。高瓴為全球領先的私人資產管理公司之一，著重於醫療健康、 製造業、綠色能源、硬科技、消費科技等領域。 本公司管理層認為本次交易反映了本公司的長期戰略為持續聚焦核心CRDMO 業務模式，專注藥物發現、實驗室測試、工藝開發及生產服務。該舉措預期能 提供財務支持助力加速全球化能力及產能發展，更好地服務客戶，為全球病患 帶來福祉。 康德弘翼及津石醫藥均為本公司的營運實體，從事於中國臨 ...

Financial Performance - Total revenue for the third quarter of 2025 reached RMB 12,057,434,626.40, representing a year-on-year increase of 15.26%[12] - The total profit for the period was RMB 5,129,651,792.47, showing a significant increase of 82.89% compared to the same quarter last year[12] - Net profit attributable to shareholders was RMB 3,514,630,329.36, reflecting a growth of 53.27% year-on-year[12] - The basic earnings per share for the quarter was RMB 1.24, an increase of 55.00% compared to the same period last year[12] - The company reported a net profit attributable to shareholders of RMB 3.25 billion, a 53.27% increase compared to the previous period[17] - The total profit increased by 82.89% year-on-year, driven by a focus on enhancing CRDMO business operations[17] - Net profit for Q3 2025 was RMB 3,547,837 thousand, a 39.2% increase from RMB 2,549,030 thousand in Q3 2024[52] - The net profit attributable to the parent company for the first three quarters of 2025 was RMB 11,801.9 million, a significant increase of 81% from RMB 6,532.9 million in the same period of 2024[63] Revenue Growth - The company achieved operating revenue of RMB 32.86 billion for the first three quarters of 2025, representing an 18.6% year-on-year growth[23] - Continuous operating business revenue grew by 22.5% year-on-year, with chemical business revenue reaching RMB 25.98 billion, up 29.3%[23] - Revenue for Q3 2025 reached RMB 12,044,962 thousand, a 19.7% increase from RMB 10,063,435 thousand in Q3 2024[51] - Total revenue for the first three quarters of 2025 was RMB 32,450,065 thousand, a 22.4% increase from RMB 26,487,694 thousand in the same period of 2024[54] Assets and Liabilities - Total assets at the end of the reporting period amounted to RMB 94,606,135,416.07, up 17.78% from the previous year[13] - Total liabilities as of September 30, 2025, were RMB 23,133.6 million, compared to RMB 21,240.2 million at the end of 2024, showing an increase of 9%[58] - Current assets totaled ¥53.81 billion as of September 30, 2025, compared to ¥38.69 billion at the end of 2024, representing a 39.0% growth[37] - The total current assets increased to RMB 53,812.3 million as of September 30, 2025, compared to RMB 38,690.2 million at the end of 2024, reflecting a growth of 39%[58] Cash Flow - The company reported a net cash flow from operating activities of RMB 11,412,834,667.47, which increased by 36.21% compared to the previous year[12] - Cash flow from operating activities generated ¥11.41 billion, compared to ¥8.38 billion in the same period last year, marking a 36.3% increase[46] - The company’s investment activities generated a net cash inflow of RMB 946.4 million in the first three quarters of 2025, a turnaround from a net outflow of RMB 2,866.6 million in the same period of 2024[61] Research and Development - Research and development expenses for the first three quarters of 2025 were ¥825.65 million, down from ¥954.04 million in the same period of 2024, indicating a 13.5% decrease[40] - Research and development expenses for Q3 2025 were RMB 311,732 thousand, slightly down from RMB 302,434 thousand in Q3 2024[51] Business Operations - The company continues to enhance its CRDMO business model to improve research and development efficiency for clients[10] - The company has enabled 75 products to be approved for market in the SMO business, with a cumulative total of 331 products over the past decade[24] - The company has developed a one-stop compound identification software that improves identification efficiency by 83% for nucleic acid and peptide metabolites[24] Market Position and Future Outlook - The company expects 2025 operating revenue to return to double-digit growth, with an adjusted growth rate of 17-18% and total revenue forecasted between RMB 43.5 billion and RMB 44 billion[25] - The company maintains a leading position in the Asia-Pacific industry for drug safety evaluation and continues to support clients in global licensing cooperation[24]